Monday, October 25, 2021 at 10am EDT Attend this webinar to hear about CGP, the latest in onco-innovation for genomic biomarker testing and uncover the role that Illumina and Q2 Solutions are playing in evolving the CGP testing landscape to deliver a localized testing model to support oncology precision medicine clinical trials in Europe. Lastly, the webinar will reveal the updated roadmap of Q2 Solutions’ Edinburgh Genomics laboratory.
Register free: http://www.appliedclinicaltrialsonline.com/act_w/biomaker
Join Q2 Solutions and Illumina for a joint webinar as they discuss key strategies for European oncology clinical trials and the benefits of a global laboratory network for genomic biomarker testing.
In this webinar, you will learn the science behind comprehensive genomic profiling (CGP), its advantages and the emergence of key oncology biomarkers that are acting to disrupt the CDx testing landscape. This webinar will also uncover the role that Illumina and Q2 Solutions play in building a global laboratory network to support local testing for oncology precision medicine trials. In addition, it will explore how this model accelerates timelines and removes common complications observed during biomarker translation and clinical trial testing. Lastly, the webinar will showcase the roadmap for Q2 Solution’s Edinburgh laboratory and the full suite of cutting-edge genomic solutions they provide.
In this webinar, you will learn:
Patrick Hurban, Ph.D.
Senior Director and Global Head,Translational Genomics
Patrick Hurban, Ph.D. is senior director and global head of Translational Genomics at Q2 Solutions. In this role, he is responsible for the identification and implementation of new genomic capabilities, encompassing bioinformatics and wet-laboratory methods, as well as the development and validation of genomic assays to support research and clinical programs. These include broad-based screening assays, such as exome and RNA sequencing, to highly focused expression, genotyping and sequencing assay panels that target a smaller number of genes.
Dr. Hurban has more than 25 years of experience in molecular genetics, including more than 18 years in positions of increasing responsibility in high-profile genomics-focused organizations. His research interests have focused on the genetic control of gene expression and have spanned diverse fields such as toxicology, developmental, and cancer biology.
Following a Bachelor’s degree in Biology from the University of North Carolina at Chapel Hill, he earned his Ph.D. in Human Genetics from the University of Utah in Salt Lake City before serving as a postdoctoral research fellow of the American Cancer Society in the Department of Developmental Biology at Stanford University.
Bert De Boer
Sr. Manager, Sales Specialists, Clinical Sales, EMEA
Bert de Boer has an extensive history in the clinical pathology space after working for 20 years inside hospitals, 13 of which was in the role of pathology department head. Since then, Bert has worked in various international commercial roles applying his expertise to senior marketing, sales, corporate liaison and business development roles. Additionally, Bert owned his own company for 7 years, guest lectured for GYN and NGYN Cytology and has consulted for several global companies. Currently, Bert is the Senior Manager of Illumina’s Oncology Sales Specialist team, applying his extensive knowledge in oncology, pathology and genomics to implement Illumina’s precision medicine and Oncology strategies
Business Development Analyst, CDx Partnering, EMEA
Megan Townsend’s current role involves building strategies and implementing initiatives that drive Illumina’s business development goals. Primarily Megan works to create exciting collaborations and partnership opportunities with key players across the life science ecosystem and has more recently taken a focus to supporting Illumina’s CDx partnering team. Previously, Megan has worked in market development and for the Illumina Accelerator Cambridge, supporting early-stage innovation with genomics at its centre. Megan is passionate about the utility of precision medicine in therapeutic development and patient health and believes that NGS technologies have and will continue to play a pivotal role in better understanding diseases and developing tomorrow’s medicines.